WARREN, N.J., Nov. 7, 2012 (GLOBE NEWSWIRE) -- MonoSol Rx, LLC (“MonoSol Rx”), the developer of PharmFilm® drug delivery technology, announced today that it has entered into a partnership with BiondVax, an Israeli based pharmaceutical company, to develop an oral film formulation of BiondVax’ universal flu vaccine, M-001, utilizing MonoSol Rx’s PharmFilm® delivery platform. There are significant advantages for this needle free delivery in vaccines, including ease of use, increased compliance and simplified distribution.
